Estimating the pathogen safety of manufactured human plasma products: Application to fibrin sealants and to thrombin

Transfusion

Volumn 48, Issue 8, 2008, Pages 1739-1753

  Horowitz, Bernard ^a   Busch, Michael ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

FIBRIN GLUE; FIBRINOGEN; THROMBIN;

ARTICLE; BLOOD COMPONENT; BLOOD TRANSFUSION; HEPATITIS A VIRUS; HEPATITIS B VIRUS; HEPATITIS C VIRUS; HUMAN IMMUNODEFICIENCY VIRUS; PARVOVIRUS; PLASMA; VARIANT CREUTZFELDT JAKOB DISEASE; VIRAL CONTAMINATION; VIRUS LOAD; VIRUS TRANSMISSION;

BLOOD BANKS; BLOOD COMPONENT TRANSFUSION; CREUTZFELDT-JAKOB SYNDROME; FIBRIN TISSUE ADHESIVE; FIBRINOGEN; HEPATITIS A; HEPATITIS B; HEPATITIS C; HIV INFECTIONS; HUMANS; PARVOVIRIDAE INFECTIONS; PLASMA; RISK ASSESSMENT; RISK FACTORS; SAFETY; THROMBIN; VIRAL LOAD; VIRUS DISEASES;

EID: 48249125452     PISSN: 00411132     EISSN: 15372995     Source Type: Journal    
DOI: 10.1111/j.1537-2995.2008.01717.x     Document Type: Article

References (93)

1. Key NS, Negrier C. Coagulation factor concentrates: past, present and future. Lancet 2007 370 : 439 48.
2. Abusriwil H, Stockley RA. Alpha-1-antitrypsin replacement therapy: current status. Curr Opin Pulm Med 2006 12 : 125 31.
3. Toubi E, Etzioni A. Intravenous immunoglobulin in immunodeficiency states: state of the art. Clin Rev Allergy Immunol 2005 29 : 167 72.
4. Solomon B. Intravenous immunoglobulin and Alzheimer's disease immunotherapy. Curr Opin Mol Ther 2007 9 : 79 85.
5. Laursen I, Houen G, Hojrup P, Brouwer N, Krogsoe LB, Blou L, Hansen PR. Second-generation nanofiltered plasma-derived mannan-binding lectin product: process and characteristics. Vox Sang 2007 92 : 338 50.
6. Lariviere B, Rouleau M, Picard S, Beaulieu AD. Human plasma fibronectin potentiates the mitogenic activity of platelet-derived growth factor and complements its wound healing effects. Wound Repair Regen 2003 11 : 79 89.
7. Poulle M, Burnouf-Radosevich M, Burnouf T. Large-scale preparation of highly purified human C1-inhibitor for therapeutic use. Blood Coagul Fibrinolysis 1994 5 : 543 9.
8. Jackson MR. Fibrin sealants in surgical practice: an overview. Am J Surg 2001 182 (2 Suppl 1S 7S.
9. Dorion RP, Hamati HF, Landis B, Frey C, Heydt D, Carey D. Risk and clinical significance of developing antibodies induced by topical thrombin preparations. Arch Pathol Lab Med 1998 122 : 887 94.
10. Ortel TL, Mercer MC, Thames EH, Moore KD, Lawson JH. Immunologic impact and clinical outcomes after surgical exposure to bovine thrombin. Ann Surg 2001 233 : 88 96.
11. Schoenecker JG, Johnson RK, Lesher AP, Day JD, Love SD, Hoffman MR, Ortel TL, Parker W, Lawson JH. Exposure of mice to topical bovine thrombin induces systemic autoimmunity. Am J Pathol 2001 159 : 1957 69.
12. Su Z, Izumi T, Thames EH, Lawson JH, Ortel TL. Antiphospholipid antibodies after surgical exposure to topical bovine thrombin. J Lab Clin Med 2002 139 : 349 56.
13. Streiff MB, Ness PM. Acquired FV inhibitors: a needless iatrogenic complication of bovine thrombin exposure. Transfusion 2002 42 : 18 26.
14. Lawson JH, Lynn KA, Vanmatre RM, Domzalski T, Klemp KF, Ortel TJ, Niklason LE, Parker W. Antihuman factor V antibodies after use of relatively pure bovine thrombin. Ann Thorac Surg 2005 79 : 1037 8.
15. Kamoda S, Ishikawa R, Kakehi K. Capillary electrophoresis with laser-induced fluorescence detection for detailed studies on N-linked oligosaccharide profile of therapeutic recombinant monoclonal antibodies. J Chromatogr A 2006 1133 : 332 9.
16. Hepner F, Cszasar E, Roitinger E, Lubec G. Mass spectrometrical analysis of recombinant human growth hormone (Genotropin® reveals amino acid substitutions in 2% of the expressed protein. Proteome Sci 2005 3 : 1.
17. Brand CM, Leadbeater L, Bellati G, Marotta F, Ideo G. Antibodies developing against a single recombinant interferon protein may neutralize many other interferon-alpha subtypes. J Interferon Res 1993 13 : 121 5.
18. Oberg K, Alm G, Magnusson A, Lundqvist G, Theodorsson E, Wide L, Wilander E. Treatment of malignant carcinoid tumors with recombinant interferon alfa-2b: development of neutralizing interferon antibodies and possible loss of antitumor activity. J Natl Cancer Inst 1989 81 : 531 5.
19. Berrini A, Borromeo V, Secchi C. Monoclonal antibodies can reveal immunoreactivity differences between pituitary and recombinant bovine growth hormone. Hybridoma 1994 13 : 485 9.
20. US Food and Drug Administration. Guidance for industry: Q5A viral safety evaluation of biotechnology products derived from cell lines of human or animal origin. September 1998. Available from: URL: http://www.fda.gov/cder/guidance/ q5a-fnl.pdf
21. Schreiber GB, Busch MP, Kleinman SH, Korelitz JJ. The risk of transfusion-transmitted viral infections. The Retrovirus Epidemiology Donor Study. N Engl J Med 1996 334 : 1685 90.
22. Dodd RY, Notari EP, Stramer SL. Current prevalence and incidence of infectious disease markers and estimated window-period risk in the American Red Cross blood donor population. Transfusion 2002 42 : 975 9.
23. Janssen MP, Over J, Vanderpoel CL, Cuijpers HT, Vanhout BA. A probabilistic model for analyzing viral risks of plasma-derived medicinal products. Transfusion 2008 48 : 153 62.
24. Mosesson MW. Fibrinogen and fibrin structure and functions. J Thromb Haemost 2005 3 : 1894 904.
25. Horowitz B. Blood protein derivative viral safety: observations and analysis. Yale J Biol Med 1990 63 : 361 9.
26. Hewitt PE, Llewelyn CA, Mackenzie J, Will RG. Creutzfeldt-Jakob disease and blood transfusion: results of the UK Transfusion Medicine Epidemiological Review study. Vox Sang 2006 91 : 221 30.
27. Burnouf T, Padilla A. Current strategies to prevent transmission of prions by human plasma derivatives. Transfus Clin Biol 2006 13 : 320 8.
28. Cohen MS, Pilcher CD. Amplified HIV transmission and new approaches to HIV prevention. J Infect Dis 2005 191 : 1391 3.
29. Wawer MJ, Gray RH, Sewankambo NK, Serwadda D, Li X, Laeyendecker O, Kiwanuka N, Kigozi G, Kiddugavu M, Lutalo T, Nalugoda F, Wabwire-Mangen F, Meehan MP, Quinn TC. Rates of HIV-1 transmission per coital act, by stage of HIV-1 infection, in Rakai, Uganda. J Infect Dis 2005 191 : 1403 9.
30. Pilcher CD, Joaki G, Hoffman IF, Martinson FE, Mapanje C, Stewart PW, Powers KA, Galvin S, Chilongozi D, Gama S, Price MA, Fiscus SA, Cohen MS. Amplified transmission of HIV-1: comparison of HIV-1 concentrations in semen and blood during acute and chronic infection. AIDS 2007 21 : 1723 30.
31. Fiebig EW, Wright DJ, Rawal BD, Garrett PE, Schumacher RT, Peddada L, Heldebrant C, Smith R, Conrad A, Kleinman SH, Busch MP. Dynamics of HIV viremia and antibody seroconversion in plasma donors: implications for diagnosis and staging of primary HIV infection. AIDS 2003 17 : 1871 9.
32. Katayama K, Kumagai J, Komiya Y, Mizui M, Yugi H, Kishimoto S, Yamanaka R, Tamatsukuri S, Tomoguri T, Miyakawa Y, Tanaka J, Yoshizawa H. Titration of hepatitis C virus in chimpanzees for determining the copy number required for transmission. Intervirology 2004 47 : 57 64.
33. Busch MP, Caglioti S, Robertson EF, McAuley JD, Tobler LH, Kamel H, Linnen JM, Shyamala V, Tomasulo P, Kleinman SH. Screening the blood supply for West Nile virus RNA by nucleic acid amplification testing. N Engl J Med 2005 353 : 460 7.
34. Glynn SA, Wright DJ, Kleinman SH, Hirschkorn D, Tu Y, Heldebrant C, Smith R, Giachetti C, Gallarda J, Busch MP. Dynamics of viremia in early hepatitis C virus infection. Transfusion 2005 45 : 994 1002.
35. Yoshikawa A, Gotanda Y, Minegishi K, Taira R, Hino S, Tadokoro K, Ohnuma H, Miyakawa K, Tachibana K, Mizoguchi H Japanese Red Cross NAT Screening Research Group. Lengths of hepatitis B viremia and antigenemia in blood donors: preliminary evidence of occult (hepatitis B surface antigen-negative) infection in the acute stage. Transfusion 2007 47 : 1162 71.
36. Satake M, Taira R, Yugi H, Hino S, Kanemitsu K, Ikeda H, Tadokoro K. Infectivity of blood components with low hepatitis B virus DNA levels identified in a lookback program. Transfusion 2007 47 : 1197 205.
37. Komiya Y, Katayama K, Yugi H, Mizui M, Matsukura H, Tomoguri T, Miyakawa Y, Tabuchi A, Tanaka J, Yoshizawa H. Minimum infectious dose of hepatitis B virus in chimpanzees and difference in the dynamics of viraemia between genotype A and C. Transfusion 2008 48 : 286 84.
38. Busch MP, Murthy KK, Hirschkorn DF, Herring BL, Delwart EL, Racanelli V, Rehermann B, Alter HJ. Infectivity of donations from eclipse and ramp-up stages of HCV in chimpanzees. Abstract S39-030H. Amer Assn of Blood Banks Annual Meeting 2007, Anaheim, CA., Oct 2007. Transfusion 2007 47 (9 Suppl 17A.
39. Ma M, Piatak M, Fritts L, Lu D, Lifson J, Busch MP, Miller CJ. Transmission of simian immunodeficiency virus (SIV) by plasma collected prior to detectable viremia, and infectivity of ramp-up versus chronic stages. Abstract S40-030H. Amer Assn of Blood Banks Annual Meeting 2007, Anaheim, CA, Oct 2007. Transfusion 2007 47 (9 Suppl 17A 18A.
40. Hijikata M, Shimizu YK, Kato H, Iwamoto A, Shih JW, Alter HJ, Purcell RH, Yoshikura H. Equilibrium centrifugation studies of hepatitis C virus: evidence for circulating immune complexes. J Virol 1993 67 : 1953 8.
41. Brummelhuis HG, Over J, Duivis-Vorst CC, Wilson-de Sturler LA, Ates G, Hoek PJ, Reerink-Brongers EE. Contributions to the optimal use of blood. IX. Elimination of hepatitis B transmission by (potentially) infectious plasma derivatives. Vox Sang 1983 45 : 205 16.
42. Prince AM, Horowitz B, Baker L, Shulman RW, Ralph H, Valinsky J, Cundell A, Brotman B, Boehle W, Rey F, Piet M, Reesink H, Lelie N, Tersmette M, Miedema F, Barbosa L, Nemo G, Nastala CL, Allan JS, Lee DR, Eichberg JW. Failure of a human immunodeficiency virus (HIV) immune globulin to protect chimpanzees against experimental challenge with HIV. Proc Natl Acad Sci U S A 1988 85 : 6944 8.
43. Prince AM, Pawlotsky JM, Soulier A, Tobler L, Brotman B, Pfahler W, Lee DH, Li L, Shata MT. Hepatitis C virus replication kinetics in chimpanzees with self-limited and chronic infections. J Viral Hepat 2004 11 : 236 42.
44. Bruce ME, McConnell I, Will RG, Ironside JW. Detection of variant Creutzfeldt Jakob disease infectivity in extraneural tissues. Lancet 2001 358 : 208 9.
45. Llewelyn CA, Hewitt PE, Knight RS, Amar K, Cousens S, Mackenzie J, Will RG. Possible transmission of variant Creutzfeldt-Jakob disease by blood transfusion. Lancet 2004 363 : 417 21.
46. Peden AH, Head MW, Ritchie DL, Bell JE, Ironside JW. Preclinical vCJD after blood transfusion in a PRNP codon 129 heterozygous patient. Lancet 2004 364 : 527 9.
47. Wroe SJ, Pal S, Siddique D, Hyare H, Macfarlane R, Joiner S, Linehan JM, Brandner S, Wadsworth JD, Hewitt P, Collinge J. Clinical presentation and pre-mortem diagnosis of variant Creutzfeldt-Jakob disease associated with blood transfusion: a case report. Lancet 2006 368 : 2061 7.
48. Cervenakova LO, Yakovleva O, McKenzie C, Kolchinsky S, McShane L, Drohan WN, Brown P. Similar levels of infectivity in the blood of mice infected with human-derived vCJD and GSS strains of transmissible spongiform encephalopathy. Transfusion 2003 43 : 1687 94.
49. Yunoki M, Tsujikawa M, Urayama T, Sasaki Y, Morita M, Tanaka H, Hattori S, Takechi K, Ikuta K. Heat sensitivity of human parvovirus B19. Vox Sang 2003 84 : 164 9.
50. Terpstra FG, Parkkinen J, Tolo H, Koenderman AH, Ter Hart HG, von Bonsdorff L, Torma E, van Engelenburg FA. Viral safety of Nanogam, a new 15 nm-filtered liquid immunoglobulin product. Vox Sang 2006 90 : 21 32.
51. Geng Y, Wu CG, Bhattacharyya SP, Tan D, Guo ZP, Yu MY. Parvovirus B19 DNA in Factor VIII concentrates: effects of manufacturing procedures and B19 screening by nucleic acid testing. Transfusion 2007 47 : 883 9.
52. Einarsson M, Morgenthaler JJ. Removal of viruses from plasma fractions by chromatography. Curr Stud Hematol Blood Transfus 1989 56 : 138 45.
53. Burnouf T. Chromatography in plasma fractionation: benefits and future trends. J Chromatogr B Biomed Appl 1995 664 : 3 15.
54. Lemon SM, Murphy PC, Smith A, Zou J, Hammon J, Robinson S, Horowitz B. Removal/neutralization of hepatitis A virus during manufacture of high purity, solvent/detergent factor VIII concentrate. J Med Virol 1994 43 : 44 9.
55. Griffith M. Ultrapure plasma factor VIII produced by anti-F VIII c immunoaffinity chromatography and solvent/detergent viral inactivation. Characterization of the Method M process and Hemofil M antihemophilic factor (human). Ann Hematol 1991 63 : 131 7.
56. Woese C. Thermal inactivation of animal viruses. Ann N Y Acad Sci 1960 83 : 741 51.
57. Tersmette M, deGoede RE, Over J, deJonge E, Radema H, Lucas CJ, Huisman HG, Miedema F. Thermal inactivation of human immunodeficiency virus in lyophilised blood products evaluated by ID50 titrations. Vox Sang 1986 51 : 239 43.
58. Horowitz B. Specific inactivation of viruses which can potentially contaminate blood products. Dev Biol Stand 1991 75 : 43 52.
59. Joch C. The safety of fibrin sealants. Cardiovasc Surg 2003 11 (Suppl 1 23 8.
60. Kawamura M, Sawafuji M, Watanabe M, Horinouchi H, Kobayashi K. Frequency of transmission of human parvovirus B19 infection by fibrin sealant used during thoracic surgery. Ann Thorac Surg 2002 73 : 1098 100.
61. Brown KE, Young NS, Alving BM, Barbosa LH. Parvovirus B19: implications for transfusion medicine. Summary of a workshop. Transfusion 2001 41 : 130 5.
62. Fryer JF, Delwart E, Hecht FM, Bernardin F, Jones MS, Shah N, Baylis SA. Frequent detection of the parvoviruses, PARV4 and PARV5, in plasma from blood donors and symptomatic individuals. Transfusion 2007 47 : 1054 61.
63. Foster PR. Assessment of the potential of plasma fractionation processes to remove causative agents of transmissible spongiform encephalopathy. Transfus Med 1999 9 : 3 14.
64. Reichl HE, Foster PR, Welch AG, Li Q, MacGregor IR, Somerville RA, Fernie K, Steele PJ, Taylor DM. Studies on the removal of a bovine spongiform encephalopathy-derived agent by processes used in the manufacture of human immunoglobulin. Vox Sang 2002 83 : 137 45.
65. Foster PR, Griffin BD, Bienek C, McIntosh RV, MacGregor IR, Somerville RA, Steele PJ, Reichl HE. Distribution of a bovine spongiform encephalopathy-derived agent over ion-exchange chromatography used in the preparation of concentrates of fibrinogen and factor VIII. Vox Sang 2004 86 : 92 9.
66. Foster PR, McLean C, Welch AG, Griffin BD, Hardy JC, Bartley A, MacDonald S, Bailey A. Removal of abnormal prion protein by plasma fractionation. Transfus Sci 2000 22 (1-2 53 6.
67. Foster PR, Welch AG, McLean C, Griffin BD, Hardy JC, Bartley A, MacDonald S, Bailey AC. Studies on the removal of abnormal prion protein by processes used in the manufacture of human plasma proteins. Vox Sang 2000 78 : 86 95.
68. Cervenakova L, Brown P, Hammond DJ, Lee CA, Saenko EL. Factor VIII and transmissible spongiform encephalopathy: the case for safety. Haemophilia 2002 8 : 63 75.
69. Foster PR. Plasma products. In : Turner ML, editor. Creutzfeldt-Jakob disease: managing the risk of transmission by blood, plasma, and tissues. Bethesda (MD) : AABB Press 2006. p. 188 213.
70. Tabor E. The epidemiology of virus transmission by plasma derivatives: clinical studies verifying the lack of transmission of hepatitis B and C viruses and HIV type 1. Transfusion 1999 39 : 1160 8.
71. Horowitz B, Ben-Hur E. Efforts in minimizing risk of viral transmission through viral inactivation. Ann Med 2000 32 : 475 84.
72. Wu CG, Mason B, Jong J, Erdman D, McKernan L, Oakley M, Soucie M, Evatt B, Yu MY. Parvovirus B19 transmission by a high-purity factor VIII concentrate. Transfusion 2005 45 : 1003 10.
73. Schmidt I, Blumel J, Seitz H, Willkommen H, Lower J. Parvovirus B19 DNA in plasma pools and plasma derivatives. Vox Sang 2001 81 : 228 35.
74. Blumel J, Schmidt I, Willkommen H, Lower J. Inactivation of parvovirus B19 during pasteurization of human serum albumin. Transfusion 2002 42 : 1011 8.
75. CJD Incidents Panel. Fourth Annual Report 1st September 2003 to 31st August 2004 to the Advisory Committee on Dangerous Pathogens Working Group on Transmissible Spongiform Encephalopathies. Available from: http://www.hpa.nhs. uk/infections/topics_az/cjd/report03-04.pdf
76. Roth WK, Weber M, Buhr S, Drosten C, Weichert W, Sireis W, Hedges D, Seifried E. Yield of HCV and HIV-1 NAT after screening of 3.6 million blood donations in central Europe. Transfusion 2002 42 : 862 8.
77. Stramer SL, Glynn SA, Kleinman SH, Strong DM, Caglioti S, Wright DJ, Dodd RY, Busch MP National Heart, Lung, and Blood Institute Nucleic Acid Test Study Group. Detection of HIV-1 and HCV infections among antibody-negative blood donors by nucleic acid-amplification testing. N Engl J Med 2004 351 : 760 8.
78. Coste J, Reesink HW, Engelfriet CP, Laperche S, Brown S, Busch MP, Cuijpers HT, Elgin R, Ekermo B, Epstein JS, Flesland O, Heier HE, Henn G, Hernandez JM, Hewlett IK, Hyland C, Keller AJ, Krusius T, Levicnik-Stezina S, Levy G, Lin CK, Margaritis AR, Muylle L, Niederhauser C, Pastila S, Pillonel J, Pineau J, van der Poel CL, Politis C, Roth WK, Sauleda S, Seed CR, Sondag-Thull D, Stramer SL, Strong M, Vamvakas EC, Velati C, Vesga MA, Zanetti A. Implementation of donor screening for infectious agents transmitted by blood by nucleic acid technology: update to 2003. Vox Sang 2005 88 : 289 303.
79. Schreiber GB, Glynn SA, Zerlauth G, Wright DJ, McEntire R. Estimated HIV, HCV, and HBV residual risks of source-plasma starting material for plasma derived medicinal products. Vox Sang 2008 (in press).
80. Parsyan A, Candotti D. Human erythrovirus B19 and blood transfusion - an update. Transfus Med 2007 17 : 263 78.
81. Schmidt M, Themann A, Drexler C, Bayer M, Lanzer G, Menichetti E, Lechner S, Wessin D, Prokoph B, Allain JP, Seifried E, Kai Hourfar M. Blood donor screening for parvovirus B19 in Germany and Austria. Transfusion 2007 47 : 1775 82.
82. Busch MP, Glynn SA, Stramer SL, Strong DM, Caglioti S, Wright DJ, Pappalardo B, Kleinman SH NHLBI-REDS NAT Study Group. A new strategy for estimating risks of transfusion-transmitted viral infections based on rates of detection of recently infected donors. Transfusion 2005 45 : 254 64.
83. Kleinman SH, Busch MP. Assessing the impact of HBV NAT on window period reduction and residual risk. J Clin Virol 2006 36 (Suppl 1 S23 S29.
84. Busch MP, Tobler LH, Gerlich WH, Schaefer S, Giachetti C, Smith R. Very low level viremia in HCV infectious unit missed by NAT. Transfusion 2003 43 : 1173 4.
85. Hsia CC, Purcell RH, Farshid M, Lachenbruch PA, Yu MY. Quantification of hepatitis B virus genomes and infectivity in human serum samples. Transfusion 2006 46 : 1829 35.
86. Modrof J, Berting A, Tille B, Klotz A, Forstner C, Rieger S, Aberham C, Gessner M, Kreil TR. Neutralization of human parvovirus B19 by plasma and intravenous immunoglobulins. Transfusion 2008 48 : 178 86.
87. Davenport R, Geohas G, Cohen S, Beach K, lazo A, Lucchesi K, Pehta J. Phase IV study of Plas+SD: hepatitis A (HAV) and parvovirus B19 safety results. Blood 2000 96 : 451a.
88. Doyle S, Corcoran A. The immune response to parvovirus B19 exposure in previously seronegative and seropositive individuals. J Infect Dis 2006 194 : 154 8.
89. Remington KM, Trejo SR, Buczynski G, Li H, Osheroff WP, Brown JP, Renfrow H, Reynolds R, Pifat DY. Inactivation of West Nile virus, Vaccinia virus, and viral surrogates for relevant and emergent viral pathogens in plasma-derived products. Vox Sang 2004 87 : 10 8.
90. Kreil TR, Berting A, Kistner O, Kindermann J. West Nile virus and the safety of plasma derivatives: verification of high safety margins, and the validity of predictions based on model virus data. Transfusion 2003 43 : 1023 8.
91. Kreil TR, Unger U, Orth SM, Petutschnig G, Kistner O, Berting A. H5N1 influenza virus and the safety of plasma products. Transfusion 2007 47 : 452 9.
92. Yunoki M, Yrayama T, Yamamoto I, Abe S, Ikuta K. Heat sensitivity of a SARS-associated coronavirus introduced into plasma products. Vox Sang 2004 87 : 302 3.
93. Uemura YY, Yang H, Heldebrant CM, Takechi K, Yokoyama K. Inactivation and elimination of viruses during preparation of human intravenous immunoglobulin. Vox Sang 1994 67 : 246 54.